摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl (2R,4S,5R,6R)-5-acetamido-6-((1R,2R)-3-azido-1,2-dihydroxypropyl)-4-hydroxy-2-(p-tolylthio)tetrahydro-2H-pyran-2-carboxylate | 1421518-49-1

中文名称
——
中文别名
——
英文名称
methyl (2R,4S,5R,6R)-5-acetamido-6-((1R,2R)-3-azido-1,2-dihydroxypropyl)-4-hydroxy-2-(p-tolylthio)tetrahydro-2H-pyran-2-carboxylate
英文别名
methyl (2R,4S,5R,6R)-5-acetamido-6-[(1R,2R)-3-azido-1,2-dihydroxypropyl]-4-hydroxy-2-(4-methylphenyl)sulfanyloxane-2-carboxylate
methyl (2R,4S,5R,6R)-5-acetamido-6-((1R,2R)-3-azido-1,2-dihydroxypropyl)-4-hydroxy-2-(p-tolylthio)tetrahydro-2H-pyran-2-carboxylate化学式
CAS
1421518-49-1
化学式
C19H26N4O7S
mdl
——
分子量
454.504
InChiKey
LAXOJSGRZIGNGH-DWYCWXKBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    31
  • 可旋转键数:
    9
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    165
  • 氢给体数:
    4
  • 氢受体数:
    10

反应信息

点击查看最新优质反应信息

文献信息

  • Click and Pick: Identification of Sialoside Analogues for Siglec-Based Cell Targeting
    作者:Cory D. Rillahan、Erik Schwartz、Ryan McBride、Valery V. Fokin、James C. Paulson
    DOI:10.1002/anie.201205831
    日期:2012.10.29
    Click ‘n’ chips: Azide and alkyne‐bearing sialic acids (purple diamond; see picture) were subjected to high‐throughput click chemistry to generate a library of sialic acid analogues. Microarray printing of the library and screening with the siglec family of sialic‐acid‐binding proteins, led to the identification of high‐affinity ligands for siglec‐9 and siglec‐10.
    Click 'n' 芯片:叠氮化物和含炔的唾液酸(紫色菱形;见图)经过高通量点击化学生成唾液酸类似物库。文库的微阵列打印和 siglec 唾液酸结合蛋白家族的筛选,导致了 siglec-9 和 siglec-10 的高亲和力配体的鉴定。
  • [EN] AUTOANTIGENS ENGINEERED TO SUPPRESS AUTOIMMUNE RESPONSE<br/>[FR] AUTO-ANTIGÈNES INGÉNIÉRISÉS POUR INHIBER UNE RÉPONSE AUTO-IMMUNE
    申请人:[en]OSPREY BIOPHARMACEUTICALS, INC.
    公开号:WO2024015872A2
    公开(公告)日:2024-01-18
    The present disclosure provides engineered antigen compositions that reduce immune response to the antigen in a subject having an immune response to the antigen. The present disclosure also provides pharmaceutical compositions that include such engineered autoantigens and methods for making such engineered autoantigens. Methods for using such engineered antigens as therapeutics and in research are also disclosed.
查看更多